Premium
Economic impact of 13‐valent pneumococcal conjugate vaccine in F innish adults ≥50 years with underlying chronic medical conditions
Author(s) -
Martikainen Janne A.,
Soini Erkki J.,
Laine Juha,
Åhman Heidi,
Postila Ville,
Klemets Peter
Publication year - 2014
Publication title -
journal of evaluation in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.737
H-Index - 73
eISSN - 1365-2753
pISSN - 1356-1294
DOI - 10.1111/jep.12131
Subject(s) - vaccination , medicine , pneumococcal conjugate vaccine , immunization , pneumococcal infections , economic impact analysis , pneumococcal disease , population , pediatrics , pneumococcal vaccine , environmental health , demography , immunology , streptococcus pneumoniae , civil engineering , antigen , biology , bacteria , engineering , genetics , sociology
Rationale, aims and objectives Invasive pneumococcal diseases ( IPD ) are associated with substantial burden in adults (≥50 years). Moreover, adults with vascular, metabolic or respiratory diseases have been shown to have a 3–6 times higher risk of IPD when compared with their healthy controls. These persons at higher risk are likely to benefit most from pneumococcal vaccinations. The 13‐valent pneumococcal conjugate vaccine ( PCV 13) was recently introduced to prevent the 13 most prevalent serotypes causing invasive pneumococcal disease in adults. The objective of this study was to estimate the expected 5‐year economic impact of targeted PCV 13 vaccination compared with no vaccination in F innish adults (≥50 years) at moderate or high risk for IPD . Methods A budget impact model was developed to predict the impact of PCV 13 vaccination in terms of the costs and IPD events avoided for years 2012–2016. Results Approximately 35% of the 2.2 million F inns over 50 years of age can be considered to be at moderate or high risk for IPD because of underlying chronic medical conditions. Vaccination of these people with PCV 13 could provide an estimated net budget savings of about €218 million compared with the current no‐vaccination situation over the next 5 years. Among the risk groups considered, the largest absolute net savings (€66.2 million) could be expected to be obtained by vaccinating people with heart disease, due to its high prevalence in the target population. Conclusion I n F inland, the immunization with PCV 13 vaccine, of adults (≥50 years) at moderate and high risk of IPD , is estimated to lead to substantial cost savings in the 5 years after vaccination.